Flag of the European Union EU Clinical Trials Register Help

Clinical trials for antiviral COVID-19

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    52 result(s) found for: antiviral COVID-19. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2022-002741-18 Sponsor Protocol Number: GS-US-611-6273 Start Date*: 2022-12-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression
    Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000842-32 Sponsor Protocol Number: GS-US-540-5774 Start Date*: 2020-03-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003510-12 Sponsor Protocol Number: GS-US-540-9012 Start Date*: 2020-10-02
    Sponsor Name:Gilead Sciences, Inc
    Full Title: A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002106-68 Sponsor Protocol Number: CTU/2020/354 Start Date*: 2020-07-16
    Sponsor Name:University College London Comprehensive Clinical Trial Unit
    Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
    Medical condition: SARS-CoV-2 (Corona virus) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003475-18 Sponsor Protocol Number: COV-AAT Start Date*: 2020-10-21
    Sponsor Name:Ghent University Hospital
    Full Title: The potential of oral Camostat in early COVID-19 disease in an ambulatory setting to reduce viral load and disease burden.
    Medical condition: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005247-78 Sponsor Protocol Number: OB003 Start Date*: 2022-01-19
    Sponsor Name:Oxygen Biotech s.r.o.
    Full Title: A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability ...
    Medical condition: COVID-19 patients suffering from moderate to severe pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-002060-31 Sponsor Protocol Number: WHOCOVID-19coreprotocol Start Date*: 2020-06-22
    Sponsor Name:Masaryk University
    Full Title: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001363-85 Sponsor Protocol Number: 60152610‬ Start Date*: 2020-04-23
    Sponsor Name:Odense University Hospital
    Full Title: COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial
    Medical condition: Healthy volunteer (Prophylaxis for COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049087 Antiviral prophylaxis PT
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001023-14 Sponsor Protocol Number: SG016 Start Date*: 2020-03-17
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001541-39 Sponsor Protocol Number: BEVACOR Start Date*: 2020-04-24
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19
    Medical condition: Acute respiratory distress syndrome in patients with COVID-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001663-24 Sponsor Protocol Number: INSIGHT012 Start Date*: 2021-09-20
    Sponsor Name:Office of Sponsored Projects,University of Minnesota
    Full Title: An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Out...
    Medical condition: We are investigating Coronavirus disease 2019 (COVID-19) which is predominantly a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000841-15 Sponsor Protocol Number: GS-US-540-5773 Start Date*: 2020-03-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) NL (Completed) GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002166-13 Sponsor Protocol Number: HUB-MdI-ICAT-COVID-201 Start Date*: 2020-07-09
    Sponsor Name:Dr. Ramón Lleonart Bellfill / Dr. Xavier Corbella Virós
    Full Title: Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilatio...
    Medical condition: Pneumonia caused by COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    23.0 10021881 - Infections and infestations 10084381 Coronavirus pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001614-38 Sponsor Protocol Number: S63935 Start Date*: 2020-04-22
    Sponsor Name:UZLeuven
    Full Title: Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038700 Respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002869-34 Sponsor Protocol Number: AT-03A-001 Start Date*: 2020-08-11
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003237-11 Sponsor Protocol Number: TMP-2005-2020-36 Start Date*: 2021-11-11
    Sponsor Name:Fraunhofer Gesellschaft for its Institute for translationale Medicine and Pharmacology ITMP
    Full Title: Effect of Bronchipret on antiviral immune response in patients with mild COVID-19 (BroVID)
    Medical condition: Adult patients suffering from mild COVID-19 with cough and at least one other symptoms will be recruited for this study.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10011224 Cough PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001467-82 Sponsor Protocol Number: P020.051 Start Date*: 2020-10-23
    Sponsor Name:Leiden University Medical Center
    Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19)
    Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    21.1 100000004865 10052212 Organ transplant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004743-83 Sponsor Protocol Number: SG018 Start Date*: 2020-11-09
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) PT (Completed) FR (Completed) NL (Completed) IT (Completed) DE (Completed) RO (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001390-76 Sponsor Protocol Number: ESCAPE Start Date*: 2020-04-27
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie...
    Medical condition: Covid-19 coronavirus infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001329-30 Sponsor Protocol Number: 2020P000787 Start Date*: 2020-04-09
    Sponsor Name:Massachussetts General Hospital
    Full Title: Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19
    Medical condition: ARDS caused by COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 16 23:56:35 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA